Leukemia & Lymphoma Society

Mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families.



REASONS TO GIVE

- · Highly effective at moving blood cancer treatments through the pipeline and making them accessible to patients.
- · Provides direct services (financial and other) to patients.

THINGS TO CONSIDER

· Specific focus on blood cancers.

OVERALL SCORE

8.01

Overview: Leukemia & Lymphoma Society earned a score of 8.01 out of 10.00. LLS outperformed peer organizations.

MISSION SCORE 7.58 - Superior

LLS has a clear theory of change and unclear goals. Programs are well aligned with LLS's stated mission and results are well measured. Our analysts have determined that programs can be considered effective.

FINANCIAL SCORE 8.33 - Superior

Analysts have determined that LLS is in good financial standing with minimal financial risks. These risks include:

· Funded promises

FUNDRAISING SCORE 8.67 - Superior

LLS is a top in class fundraiser. LLS has increased revenues by 10.47% in the last three years. They have well diversified revenue streams and fundraising revenues consistently cover operating expenses.

GOVERNANCE SCORE 8.17 - Superior

LLS adheres to all governance best practice standards. They indirectly involve their clientbase in organizational strategic planning and leadership representation. Management is under compensated relative to for-profit comparables

WEBSITE

https://www.LLS.org

\$470,565,000

REVENUE (most recent year)

Chronic Disease

ISSUE AREA

POPULATION

Cancer

Innovative Programs

INSIGHTS

Leverages Client Insights **Bold Strategy** Creative Fundraising Strategy

SDGs

Good Health & Well-Being

Theory of Change: LLS performs research, provides public and professional educational services and direct patient services to

ORGANIZATIONAL STRATEGY

reduce the impact of blood cancers and improve treatments.

This can be a description about this section if wanted

MISSION & PROGRAMMING

MISSION SCORE

7.58

SUPERIOR

· Improve treatment options and outcomes for blood cancer patients

PRIMARY OUTCOMES

- · Improve patient quality of life

\$312,187,000

PROGRAM EXPENSES

Research

TOP PERFORMING PROGRAM

ALIGNMENT Leukemia & Lymphoma Society's programs are well aligned with mission indicators.

ORGANIZATIONAL PROGRAMS

Outputs are consistently reported annually and outcomes could be more rigorous.

Alignment

TRANSPARENCY

Transparency

Programs, on average, show significant improvement in comparison to relevant benchmarks.

EFFICACY

% of Total Program Cost

Efficacy

Program

Patient and Community Service	****	****	***	64%
Research	****	****	****	16%
Public Health Education	****	****	****	15%
Professional Education	****	****		5%

of revenue lines.

FUNDRAISING EVALUATION

FUNDRAISING SCORE 8.67

Fundraising ratings are focused on evaluating the effectiveness of fundraising dollars and assessing the potential risk

SUPERIOR

TOTAL REVENUE

\$470,565,000

LLS's total revenue has increased by 10.47% over the last three years.

Contribution revenue to LLS has remained flat over the last three years.

TOTAL CONTRIBUTIONS

\$248,523,000

on fundraising over the last three years.

FUNDRAISING MARGIN

89%

LLS has not changed the amount spent

risks with opportunities to invest in the organization.

FINANCIAL PERFORMANCE

FINANCIAL SCORE RISKS

Financial ratings are focused on the optimization of financial resources to achieve impact goals by weighing financial

SUPERIOR

TOTAL ASSETS

\$591,179,000

LLS has grown their total assets by

27.93% over the last three years.

8.33

TOTAL INVESTMENTS \$520,898,000

"\$62,257,856"

· Funded promises

LLS's investments have grown at a rate

Little to No Restricted Capital

RESTRICTED ASSETS

0.47

RESTRICED ASSET RATIO

0.05

of 35.49% over the last three years while operating expenses have grown at a rate

TOTAL ASSETS **DEBT RATIO**

0.09

Financial Metric Comparison

*			
Leukemia & Lymphoma Society	"\$591,179,000"	0.66	0.47

Governance and Management ratings are focused on evaluating representation - both of demographics and the client base - on the board and upper management, differentiating aspects of the board, and management pay as it compares to for-profit companies with similar revenues.

GOVERNANCE & MANAGEMENT

GOVERNANCE SCORE

8.17

ORGANIZATION NAME

American Kidney Fund

MANAGEMENT COMPENSATION

SUPERIOR

of for-profit comparables

Organizational leadership and board member

professional backgrounds represent all key

functions.

Under Compensated

Management is compensated at 77.18% of that

PROFESSIONAL EXPERIENCE

LLS has clients directly represented in organizational leadership.

> **BOARD MEMBERS** 19

CLIENT INVOLVEMENT

LLS adheres to all governance best practice standards.

BOARD STANDARDS

LLS has some representation amongst

organizational leadership.

DIVERSITY